A clinical study of CID-103 for the treatment of antibody-mediated rejection in kidney transplant recipients
Latest Information Update: 23 Aug 2024
At a glance
- Drugs TSK 011010 (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions
Most Recent Events
- 16 Aug 2024 According to CASI Pharmaceuticals media release, company anticipate to submit an IND for CID-103 in AMR in the fourth quarter of this year.
- 28 Jun 2024 New trial record
- 26 Jun 2024 According to CASI Pharmaceuticals media release, Company is planning to submit an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration for CID-103 for the treatment of antibody-mediated rejection ("AMR") in kidney transplant recipients by the end of 2024.